Nanobodies — also called single-domain antibodies or VHH antibodies — are minimal antibody fragments derived from the variable regions of heavy-chain antibodies (HcAbs) found exclusively in camelids such as alpacas and camels. Their distinguishing properties include a small molecular weight (~15 kDa), exceptional thermostability, strong hydrophilicity, and an unusual ability to access recessed or cryptic epitopes that conventional antibodies cannot reach. These characteristics make nanobodies attractive tools for diagnostics, targeted therapy, and molecular imaging.
The alpaca (Vicugna pacos) is the most widely used host animal for nanobody generation. In practice, however, alpacas mount relatively weak immune responses to many recombinant antigens — including proteins, peptides, and inactivated viruses. Compounding this, their large body size (50–80 kg in adulthood) makes repeated immunizations operationally demanding. As a result, adjuvant selection has emerged as one of the most consequential variables determining the speed, efficiency, and ultimate success of a nanobody discovery campaign.
Freund's Adjuvant remains the most commonly used option in camelid immunization, but it carries well-documented drawbacks in this specific context:
• Significant toxicity. Complete Freund's Adjuvant (CFA) contains heat-killed Mycobacterium tuberculosis, which frequently causes swelling, granuloma formation, ulceration, and even severe arthritis at the injection site — raising serious animal welfare concerns.
• Laborious preparation. As a water-in-oil emulsion, Freund's Adjuvant must be thoroughly emulsified with the antigen before each use, typically requiring 30–60 minutes of active work. The shear forces generated during this process can disrupt the native conformation of protein antigens, potentially reducing immunogenicity.
• Suboptimal VHH yields. Extensive serum profiling has consistently shown that Freund's Adjuvant predominantly drives IgG1-class conventional antibody responses in camelids, with a disproportionately low VHH fraction. This directly limits library quality and the efficiency of downstream clone selection.
These limitations have prompted researchers and biopharmaceutical teams to explore adjuvant alternatives specifically tailored to camelid biology.
An immunological adjuvant is a substance that non-specifically amplifies the immune response to a co-administered antigen — boosting its recognition by the immune system, shaping the type of response generated, or prolonging the duration of immunity. Adjuvants are not themselves antigenic, but their effects on antigen-presenting cells and immune signaling can dramatically increase the potency of the immune response.
Many research-grade antigens — recombinant proteins, synthetic peptides, subunit vaccine components — are structurally simple and inherently weakly immunogenic. Administered alone, they often fail to elicit a response of sufficient magnitude. Adjuvants compensate for this deficiency.
• Overcoming poor immunogenicity. Adjuvants enhance antigen visibility to the immune system, often by converting soluble antigens into particulate forms that are more readily taken up by antigen-presenting cells (APCs).
• Directing the type of immune response. Different adjuvants selectively promote Th1 (cellular immunity) or Th2 (humoral immunity) responses, enabling researchers to align the immune profile with their experimental objectives — humoral immunity for antibody generation, cellular immunity for tumor immunology applications.
• Sustaining the immune response. Through the depot effect — slow, sustained antigen release from the injection site — adjuvants prolong the window of immune activation, reduce the number of booster doses required, and lower overall experimental complexity.
Adjuvant-mediated immune enhancement operates through four converging mechanisms:
• Enhanced antigen presentation. Adjuvants promote antigen uptake, processing, and presentation by dendritic cells (DCs) and macrophages; upregulate co-stimulatory molecules (CD80, CD86) and MHC expression; and amplify T and B cell activation.
• Innate immune activation. Through pattern recognition receptor (PRR) signaling — including TLR2, TLR4, and TLR9 — adjuvants directly activate innate immune cells and trigger cytokine cascades (IL-1β, IL-12, IFN-γ, among others).
• Local inflammatory induction. Adjuvants drive localized inflammation at the injection site, releasing chemokines (CCL3, CCL5) that recruit additional immune cells, slow antigen clearance, and extend the immunization window.
• Response polarization. By modulating the Th1/Th2 balance, adjuvants determine whether cellular or humoral immunity predominates and influence the distribution of antibody isotypes produced.
In camelid immunization practice, Freund's Adjuvant (water-in-oil) and water-soluble adjuvants — typified by Adjuvant Camelid — represent the two dominant approaches. They differ in fundamental ways across mechanism, handling, safety, and immunological output.
Parameter | Freund's Adjuvant (CFA/IFA) | Water-Soluble Adjuvant (Adjuvant Camelid) |
Formulation | Water-in-oil (W/O) emulsion | Fully aqueous solution |
Active components | CFA: mineral oil + lanolin + heat-killed M. tuberculosis IFA: mineral oil + lanolin | Aqueous formulation; all components non-toxic |
Preparation | Antigen must be emulsified before use (≥30–60 min); specialized technique required | Mix 1:1 with antigen, vortex briefly, inject immediately |
Antigen conformation | Emulsification shear forces may disrupt native protein structure | Aqueous system preserves native antigen conformation |
Adverse effects | CFA causes erythema, ulceration, granuloma, and potentially arthritis at injection site | Minimal adverse effects; no rejection response; well tolerated |
Immune response bias | CFA → predominantly Th1; IFA → predominantly Th2 | Induces robust dual cellular and humoral immunity |
VHH antibody output | Predominantly conventional IgG1; low VHH proportion | Substantially elevated VHH proportion and titer |
Immunization interval | Typically every 2–3 weeks | Can be shortened to every 7–14 days |
Administration routes | Subcutaneous or intramuscular injection | Subcutaneous, intramuscular, or intraperitoneal |
Human applicability | Animal research only; contraindicated in humans | Non-toxic formulation; safe composition |
Freund's Adjuvant is one of the most widely used adjuvants in preclinical research and comes in two forms:
• Incomplete Freund's Adjuvant (IFA) consists of liquid paraffin and lanolin in a 2:1 (v/v) ratio, forming a water-in-oil emulsion. The Sigma standard product (F5506) contains 0.85 mL paraffin oil and 0.15 mL mannide monooleate per mL.
• Complete Freund's Adjuvant (CFA) builds on IFA by incorporating heat-killed Mycobacterium tuberculosis at a final concentration of 2–20 mg/mL. The Sigma standard product (F5881) contains 1 mg of heat-killed, desiccated M. tuberculosis H37Ra (ATCC 25177), 0.85 mL paraffin oil, and 0.15 mL mannide monooleate per mL.
1. Depot Effect: Sustained Antigen Exposure
The viscous water-in-oil emulsion encapsulates the antigen at the injection site, creating a stable antigen reservoir that releases its payload slowly over several weeks. This retards antigen degradation, prolongs the window of immune recognition, and reduces the total number of immunizations required.
2. Immune Cell Recruitment and APC Activation
Cell wall components of M. tuberculosis in CFA — including lipoarabinomannan and peptidoglycan — act as TLR2 and TLR4 ligands, triggering localized inflammation and releasing chemokines (CCL3, CCL5) that recruit macrophages and DCs to the injection site. These APCs upregulate co-stimulatory molecules (CD80, CD86) and secrete pro-inflammatory cytokines (IL-1β, IL-12), substantially enhancing antigen presentation efficiency.
3. Immune Response Polarization
CFA drives Th0 differentiation toward a Th1 phenotype by inducing IL-12 and IFN-γ, reinforcing cellular immune responses. IFA, lacking the mycobacterial component, leverages the depot effect to promote Th2 responses (via IL-4, IL-5, IL-6), favoring humoral antibody production. CFA engages TLR2, TLR4, and TLR9 and predominantly induces Th1 cellular immunity; IFA primarily drives Th2 humoral responses.
The conventional protocol calls for CFA at the primary immunization (1:1 v/v with antigen), followed by IFA for all subsequent boosts — avoiding the severe inflammation associated with repeated CFA administration. Some protocols omit adjuvant for later immunizations, in which case antigen doses should be increased 10–20-fold to compensate.
Thorough emulsification of Freund's Adjuvant with the antigen is mandatory before use. Five approaches are commonly employed:
• Mechanical vortex: Antigen and adjuvant are combined in an Eppendorf tube and vortexed vigorously for 5–30 minutes until a stable, viscous emulsion forms. Carrying out this step at 4°C helps prevent heat-induced antigen denaturation.
• Syringe-to-syringe mixing: Equal volumes of adjuvant and antigen are loaded into a syringe and emulsified by repeatedly pushing the plunger, or by alternating between two syringes connected via a three-way stopcock, for 30–60 minutes. This method minimizes antigen loss and suits small-volume preparations.
• Mechanical stirrer: A dedicated emulsification device is used; 1–10 mL volumes are typically emulsified within 3–5 minutes (10 minutes maximum).
• Mortar and pestle: Adjuvant is placed in a sterile mortar; antigen is added dropwise with continuous unidirectional grinding. Suitable for larger volumes, though significant antigen loss due to vessel wall adherence is a known limitation.
• Ultrasonication: A sonicator with a narrow probe processes the antigen-adjuvant mixture. Applicable for hard-to-emulsify samples, but frequency, duration, and temperature must be carefully controlled; free radical generation during sonication poses a risk of antigen damage.
Quality check: a drop of the finished emulsion placed on a room-temperature water surface should hold together as a discrete bead without dispersing — confirming a successful water-in-oil preparation.
• CFA induces severe local adverse reactions — erythema, tissue necrosis, granuloma — with meaningful implications for laboratory animal welfare.
• The mineral oil phase is poorly metabolized in vivo, with potential long-term effects at the injection site.
• Emulsification is laborious, and the shear forces involved can disrupt native antigen conformation.
• Freund's Adjuvant is strictly limited to preclinical animal research and is contraindicated for any human use.
Adjuvant Camelid was developed directly in response to the limitations Freund's Adjuvant poses in camelid immunization. Following two years of formulation development, AlpVHHs launched the product commercially in 2023. It has since been evaluated by a broad range of nanobody researchers and has demonstrated consistent advantages over Freund's Adjuvant across multiple head-to-head antigen immunization comparisons.
• Markedly elevated VHH proportion and serum titer. This is the defining differentiator of Adjuvant Camelid relative to Freund's Adjuvant, with direct consequences for library quality and screening throughput.
• Potent dual cellular and humoral immune activation. The adjuvant is designed to simultaneously drive both arms of the adaptive immune response, generating durable immune memory with both cellular and humoral components.
• Aqueous formulation — no emulsification required; antigen conformation preserved. In sharp contrast to Freund's oil-based system, the water-soluble formulation eliminates the emulsification step entirely and maintains the native three-dimensional structure of the antigen, favoring induction of antibodies targeting conformational epitopes.
• Excellent safety and tolerability profile. All components are non-toxic and do not elicit rejection responses. Injection sites show no ulceration or granuloma formation, fully meeting contemporary laboratory animal welfare standards.
• Flexible administration routes. Compatible with subcutaneous, intramuscular, and intraperitoneal injection; multi-site subcutaneous or intramuscular dosing is recommended for best results.
• Compressed immunization schedule. A 7-day interval is recommended between the prime and the first boost, with subsequent doses at 7–14 day intervals. A complete schedule comprises 4–5 injections, with 1–2 additional doses if serum titers remain below the target threshold.
Preparation is straightforward: combine the antigen with an equal volume of Adjuvant Camelid (minimum 500 µL adjuvant recommended) in an Eppendorf tube, vortex thoroughly, and the mixture is ready for injection. The entire process takes only minutes and requires no specialized equipment or training.
For whole-cell immunization: combine 2 × 10⁷ cells (500 µL) with 500 µL of adjuvant and administer by multi-site subcutaneous injectio
Alpacas were immunized with antigen formulated in either Freund's Adjuvant or Adjuvant Camelid. Peripheral blood was collected 7 days after the fourth immunization. Two secondary antibodies were used in parallel: Anti-Alpaca IgG (H+L) AlpHcAbs® Goat antibody (HRP) to measure total IgG titer, and Anti-VHH AlpHcAbs® Rabbit antibody (HRP) to measure VHH-specific titer.
Case 1: Human PDL1-Fc
Alpacas were immunized four times with Human PDL1-Fc antigen formulated in either Freund's Adjuvant or Adjuvant Camelid. Total IgG and VHH serum titers were compared between groups at study endpoint.
Case 2: Human TSLP
The same four-immunization protocol was applied using Human TSLP as the target antigen. Total IgG and VHH titers were measured and compared across both adjuvant groups.
VHH antibodies originate from the unique heavy-chain antibodies (HcAbs) found in camelids. During affinity maturation, B cells within germinal centers undergo somatic hypermutation (SHM) and positive selection, progressively enriching for clones with high antigen affinity. The central objective of a nanobody campaign is to maximize both the proportion of VHH within the total antibody repertoire and the affinity of those VHH for the target antigen (reflected as a low KD value) — and both goals are shaped by the immune response profile the adjuvant elicits.
Freund's Adjuvant — particularly CFA — is a potent TLR2/TLR4 agonist by virtue of its mycobacterial components, and it strongly polarizes the immune response toward a Th1 phenotype. While this confers robust overall immunostimulation, the resulting response in camelids is skewed toward conventional IgG1 production, with limited promotion of the IgG2 and IgG3 heavy-chain antibody subclasses from which VHH are derived. Consistent with this mechanistic picture, serum profiling across multiple studies confirms that the VHH fraction remains substantially lower after Freund's Adjuvant immunization than would be desirable for efficient library construction.
Adjuvant Camelid was formulated with camelid immunobiology specifically in mind. It simultaneously activates both cellular and humoral immune arms while selectively boosting VHH production — yielding both a higher VHH proportion and a higher VHH-specific titer compared with Freund's Adjuvant.
Using Human PDL1-Fc and Human TSLP as model antigens, alpacas received four immunizations under each adjuvant protocol. Total IgG was measured with an Anti-Alpaca IgG (H+L) antibody; VHH-specific titer was assessed with an Anti-VHH antibody.
Key findings: Total IgG titers were comparable between the two adjuvant groups, indicating similar overall immunostimulatory capacity. VHH titers, however, were significantly higher with Adjuvant Camelid. Consistent results across both PDL1-Fc and TSLP antigens confirm that this advantage in VHH-specific immune activation is robust and reproducible — not antigen-dependent.
Adjuvant selection should be guided by five considerations:
• Target antibody class. For nanobody (VHH) discovery, a water-soluble adjuvant such as Adjuvant Camelid — which demonstrably elevates VHH proportions — should be the default choice. For conventional polyclonal antibody production, Freund's Adjuvant remains a viable option for broadly elevating antibody titers.
• Antigen immunogenicity. For weakly immunogenic antigens (small peptides, poorly soluble proteins), CFA's potent TLR agonist activity can provide stronger APC activation. Adjuvant Camelid is also applicable in these settings and offers significantly simpler handling.
• Antigen conformational sensitivity. When preserving native antigen structure is essential for generating conformational epitope-directed antibodies, a water-soluble adjuvant is strongly preferred — emulsification-induced denaturation is a real risk with Freund's systems.
• Animal welfare. For large animals such as alpacas, the granuloma and ulceration associated with repeated Freund's Adjuvant injections carry meaningful welfare costs. Water-soluble adjuvants avoid these concerns entirely.
• Timeline and throughput. When timelines are compressed, Adjuvant Camelid's support for 7-day immunization intervals can meaningfully shorten the total elapsed time from campaign initiation to library-quality serum.
Antigen Type | Recommended Adjuvant | Protocol | Key Considerations |
Recombinant protein (high immunogenicity) | Adjuvant Camelid | Mix 1:1 (v/v); multi-site subcutaneous injection; 7–14 day intervals | Simple mixing; no emulsification needed |
Recombinant protein (low immunogenicity) | Adjuvant Camelid or CFA prime + IFA boost | Adjuvant Camelid: as above CFA protocol: prime with CFA (1:1), boost with IFA | Freund's protocol requires thorough emulsification (≥30 min) |
Peptides / small-molecule haptens | CFA prime + IFA boost; or carrier-conjugated antigen + Adjuvant Camelid | Prime with CFA (1:1 emulsion); subsequent boosts with IFA Small molecules require conjugation to a carrier protein (e.g., KLH) | Haptens alone are non-immunogenic; carrier conjugation is mandatory |
Whole cells | Adjuvant Camelid | 2 × 10⁷ cells (500 µL) + 500 µL adjuvant; multi-site subcutaneous injection | Suitable for whole-cell antigen immunization protocols |
Virus-like particles / inactivated viruses | Adjuvant Camelid | Mix 1:1 (v/v); subcutaneous or intramuscular injection | Observe biosafety level requirements for antigen preparation |
Adjuvants are foundational tools in the nanobody discovery pipeline. The evolution from Freund's Adjuvant to purpose-engineered, camelid-specific solutions like Adjuvant Camelid reflects a broader shift in the field — toward adjuvant strategies that optimize not just immune activation, but the specific quality of immune response most relevant to VHH generation.
Freund's Adjuvant, as the established benchmark, retains real utility for certain scenarios — particularly weakly immunogenic antigens and conventional polyclonal antibody campaigns — backed by decades of accumulated data. But its handling complexity, adverse effect burden, and inherently low VHH yields make it a poor fit for modern nanobody discovery workflows where efficiency and library quality are paramount.
Adjuvant Camelid represents a purpose-built alternative that addresses these shortcomings directly. By combining an aqueous, conformation-friendly formulation with immune activation tailored to camelid biology, it delivers consistently higher VHH titers with simpler handling and a superior animal welfare profile.
In practice, the optimal adjuvant choice will always depend on a constellation of factors — antigen immunogenicity, conformational sensitivity, target antibody class, animal welfare constraints, and project timeline. Systematically evaluating these variables before committing to an immunization strategy is the surest path to generating the high-quality, VHH-enriched immune responses that underpin successful nanobody discovery, affinity optimization, and functional characterization.
This article is based on publicly available scientific literature and experimental data and is intended for reference by research professionals. For product specifications and technical documentation, please contact the AlpVHHs technical Manager.
Regardless of adjuvant choice, immune response quality should be verified at the end of the immunization schedule:
• Serum titer measurement. ELISA-based quantification of both Total IgG and VHH-specific titers provides a direct readout of response magnitude. Blood is typically collected from the jugular vein one week after the final dose.
• Go/no-go criteria. If titers meet the predefined threshold, the project proceeds to peripheral blood lymphocyte isolation and library construction. If titers remain insufficient, one to two additional immunizations are administered before reassessment.
AlpVHHs is a supplier focused on the research, development, and service of nanobody products. The company employs phage display (Phage Display) and yeast surface display (Yeast Surface Display) technology platforms to develop high-quality recombinant nanobodies and provide innovative tools based on nanobodies to scientists worldwide. AlpVHHs is committed to advancing nanobody technology from frontier research to everyday scientific application, enabling every researcher to achieve experimental goals with lower technical barriers and greater reliability.
Relate products:
Code | Description | Applications | Size |
600-000-001 | Immunization | 10mL | |
600-000-002 | Immunization | 10mL | |
600-000-003 | Immunization | 10mL | |
600-000-011 | Immunization | 1mg |
1. Why is adjuvant selection so critical for nanobody (VHH) discovery in alpacas?
Alpacas often exhibit relatively weak immune responses to many recombinant antigens like proteins and peptides. Given their large body size, which makes frequent immunization operationally demanding, choosing the right adjuvant is essential to amplify the immune response, shape the antibody class produced, and ensure the ultimate success of the nanobody discovery campaign.
2. What are the primary drawbacks of using traditional Freund's Adjuvant in camelid immunization?
Freund's Adjuvant, while potent, has significant limitations:
Toxicity: It can cause severe local inflammation, granulomas, and arthritis, leading to animal welfare concerns.
Complex Preparation: It requires 30–60 minutes of intensive emulsification, and the resulting shear forces can damage the native conformation of protein antigens.
Low VHH Yield: It primarily drives conventional IgG1 responses rather than the desired heavy-chain-only antibodies (VHH), limiting the quality of the resulting library.
3. How does "Adjuvant Camelid" address the limitations of Freund’s Adjuvant?
"Adjuvant Camelid" is specifically designed for camelids to solve the pain points of traditional adjuvants. It is a water-soluble formulation that requires simple mixing without complex emulsification, thereby preserving the antigen's native conformation. Most importantly, it is non-toxic and is engineered to specifically increase the proportion and titer of single-domain antibodies (VHH).
4. Can I use Complete Freund's Adjuvant (CFA) for every injection in my immunization protocol?
No. CFA is typically only used for the first (prime) injection because of its extreme potency and potential for causing severe tissue damage. For subsequent booster injections, researchers should use Incomplete Freund’s Adjuvant (IFA)—which lacks the heat-killed mycobacteria—or a different, milder adjuvant to maintain the immune response while minimizing side effects.
5. What are the key differences between the "Depot Effect" of aluminum salts and the mechanism of CFA?
Aluminum Salts: Primarily act through a "Depot Effect," where they trap the antigen at the injection site for slow release, mainly inducing a Th2-type (humoral) immune response.
CFA: Also creates a slow-release "antigen reservoir" but adds a powerful immune-stimulating component (mycobacteria) that activates Antigen Presenting Cells (APCs) via TLR receptors. This triggers a much stronger, mixed Th1/Th2 response, which is often necessary for low-immunogenicity antigens.
[1]. Hamers-Casterman C, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446-448.
[2]. Muyldermans S. Nanobodies: Natural Single-Domain Antibodies. Annual Review of Biochemistry. 2013;82:775-797.
[3]. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228(4705):1315-1317.
[4]. Thermo Fisher Scientific. Overview of Immunoprecipitation (IP). Technical Resource Library.
[5]. Linical Point Biologics / AlpVHHs. Adjuvant Camelid & AlpSdAbs® Technical Documentation. Official Product Manual. 2023-2024.
